The World Health Organization (WHO) 5th edition classifies AML with mutated NPM1 as a distinct entity, despite the blast count, perhaps due to the rapid time to progression from myelodysplastic syndrome (MDS) or myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) [52]. This evidence concerns the gene NPM1 and myeloproliferative disorder.